Coherus’ Lucentis Biosimilar Outstrips Biogen Rival One Month After Launch
$100m In Cimerli Revenues Anticipated In 2023, Q Code Submitted
One month after launching its Cimerli ranibizumab biosimilar to Lucentis, Coherus BioSciences’ management explained how it had stolen a march on the earlier introduced Byooviz product launched by Biogen/Samsung Bioepis.
